Three cases of anti-TNF induced myositis and literature review.

Abstract

Anti-tumor necrosis factor drugs are frequently preferred in the treatment of rheumatologic diseases and other inflammatory diseases. The development of myositis after using anti-tumor necrosis factor drugs is a rare clinical condition. Here we aimed to report cases who developed myositis after using anti-tumor necrosis factor drugs and review the current literature. We report two cases of rheumatoid arthritis and a case of ankylosing spondylitis developed idiopathic inflammatory myopathy following anti-tumor necrosis factor therapy. In conclusion, myositis could develop during anti-tumor necrosis factor therapy, so these patients should be evaluated carefully initially for myositis and should be closely monitored due to the potential for developing myositis in treatment process.

• Authors: Orhan Zengin, Mustafa Erkut Onder, Samet Alkan, Gezmiş Kimyon, Nergis Hüseynova, Zeynep Hanım Demir, Bünyamin Kısacık, Ahmet Mesut Onat
• Journal: Revista brasileira de reumatologia (Rev Bras Reumatol Engl Ed) 2017 Nov - Dec Vol. 57 Issue 6 Pg. 590-595 ISSN: 2255-5021 [Electronic] Brazil
• PMID: 29173693 (Publication Type: Case Reports, Journal Article, Review)
• Copyright: Copyright © 2016 Elsevier Editora Ltda. All rights reserved.

Chemical References

• Antirheumatic Agents
• Tumor Necrosis Factor-alpha
• Adalimumab
• Etanercept

Topics

• Adalimumab (administration & dosage, adverse effects)
• Adult
• Antirheumatic Agents (adverse effects)
• Arthritis, Rheumatoid (drug therapy)
• Etanercept (administration & dosage, adverse effects)
• Female
• Humans
• Male
• Myositis (chemically induced, diagnosis)
• Spondylitis, Ankylosing (drug therapy)
• Tumor Necrosis Factor-alpha (antagonists & inhibitors)
• Young Adult